A Phase II, Open-label Study of ONC201 in Adults With Recurrent High-grade Glioma
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs ONC 201 (Primary)
- Indications Glioma
- Focus Therapeutic Use
- Sponsors Oncoceutics
- 03 Nov 2017 According to an Oncoceutics media release, first patient has been treated.
- 03 Nov 2017 According to an Oncoceutics media release, this trial is led by Andrew Chi from New York University.
- 30 Oct 2017 Status changed from not yet recruiting to recruiting.